Resolution scores $83m to develop macrophage cell therapies [Yahoo! Finance]
AstraZeneca PLC - American Depositary Shares (AZN)
Last astrazeneca plc - american depositary shares earnings: 2/5 04:00 pm
Check Earnings Report
US:NYSE Investor Relations:
astrazeneca.com/investor-relations.html
Company Research
Source: Yahoo! Finance
The UK-based company plans to use the money to finance the Phase I/II EMERALD trial for its lead candidate, RTX001, as a treatment for end-stage liver disease. Resolution also intends to direct the funds to expand its pipeline in other inflammatory and fibrotic indications, including graft-vs-host disease (GvHD) and lung fibrosis. RTX001 is an engineered autologous macrophage cell therapy. Macrophages act as effector cells of the innate immune system and play an important role in mediating inflammation and eliminating foreign organisms. RTX001 is designed to decrease fibrosis and inflammation in patients with end-stage liver disease. The open-label Phase I/II EMERALD trial will evaluate the therapy in the indication, with recruitment expected to start across the UK and Spain by the end of the year. The trial's primary endpoint will measure clinical events including all-cause mortality. Resolution previously raised £22m in Series A funding in 2020. Both financing rounds were led
Show less
Read more
Impact Snapshot
Event Time:
AZN
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
AZN alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
AZN alerts
High impacting AstraZeneca PLC - American Depositary Shares news events
Weekly update
A roundup of the hottest topics
AZN
News
- AstraZeneca's Calquence sNDA Gets FDA Priority Tag for Expanded Use [Yahoo! Finance]Yahoo! Finance
- Owkin and AstraZeneca to develop AI tool for breast cancer testing [Yahoo! Finance]Yahoo! Finance
- CALQUENCE® (acalabrutinib) granted Priority Review in the US for patients with untreated mantle cell lymphomaBusiness Wire
- Arcus and AstraZeneca enter trial collaboration for renal cancer treatment [Yahoo! Finance]Yahoo! Finance
- 3 UK Stocks Estimated To Be Trading Below Their Intrinsic Value [Yahoo! Finance]Yahoo! Finance
AZN
Sec Filings
- 10/1/24 - Form 6-K
- 9/26/24 - Form 6-K
- 9/23/24 - Form 6-K
- AZN's page on the SEC website